GAMMA Investing LLC Grows Position in Vaxcyte, Inc. (NASDAQ:PCVX)

GAMMA Investing LLC lifted its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 2,631.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,780 shares of the company's stock after purchasing an additional 9,422 shares during the period. GAMMA Investing LLC's holdings in Vaxcyte were worth $369,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in PCVX. Capital Research Global Investors grew its holdings in shares of Vaxcyte by 26.8% during the fourth quarter. Capital Research Global Investors now owns 6,210,523 shares of the company's stock worth $508,393,000 after purchasing an additional 1,312,302 shares during the last quarter. Norges Bank acquired a new stake in Vaxcyte during the 4th quarter valued at approximately $90,069,000. Vanguard Group Inc. increased its position in Vaxcyte by 4.6% during the 4th quarter. Vanguard Group Inc. now owns 11,961,687 shares of the company's stock valued at $979,184,000 after purchasing an additional 521,204 shares during the period. Paradigm Biocapital Advisors LP increased its position in Vaxcyte by 57.3% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,422,787 shares of the company's stock valued at $116,469,000 after purchasing an additional 518,255 shares during the period. Finally, Lazard Asset Management LLC acquired a new stake in Vaxcyte during the 4th quarter valued at approximately $39,846,000. 96.78% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Needham & Company LLC reiterated a "buy" rating and set a $90.00 price target on shares of Vaxcyte in a report on Tuesday, April 8th. Evercore ISI raised shares of Vaxcyte to a "strong-buy" rating in a research note on Monday, March 31st. Bank of America cut their target price on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Cantor Fitzgerald began coverage on Vaxcyte in a research report on Tuesday, April 22nd. They set an "overweight" rating on the stock. Finally, Guggenheim reaffirmed a "buy" rating and set a $160.00 target price on shares of Vaxcyte in a research report on Wednesday, March 12th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Vaxcyte has an average rating of "Buy" and an average target price of $136.50.

Vaxcyte Price Performance

Shares of NASDAQ:PCVX traded down $0.53 during trading on Friday, reaching $32.87. 2,520,867 shares of the stock were exchanged, compared to its average volume of 1,456,359. The firm has a market cap of $4.24 billion, a price-to-earnings ratio of -8.24 and a beta of 1.20. The stock has a fifty day moving average of $33.00 and a two-hundred day moving average of $60.98. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same quarter last year, the firm earned ($0.85) earnings per share. Sell-side analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.